Business Context and Reporting Period
This Form 8-K is a current report filed by Pieris Pharmaceuticals, Inc. (not Palvela Therapeutics, Inc.) on July 26, 2018, regarding events occurring at the Annual Meeting of Stockholders held on July 24, 2018. The registrant is incorporated in Nevada and is classified as an Emerging Growth Company.
Key Financial Metrics
This filing is a corporate governance report and does not contain financial performance data. There are no disclosures regarding revenue, profit, cash flow, margins, debt, or liquidity in this document.
Material Changes and Corporate Actions
The filing details the following material corporate actions approved by stockholders:
- Election of Directors: Christopher Kiritsy and Jean-Pierre Bizzari were elected as Class I directors for three-year terms expiring in 2021.
- Equity Incentive Plan Approval: Stockholders approved the 2018 Employee, Director and Consultant Equity Incentive Plan (2018 EIP).
- Stock Purchase Plan Approval: Stockholders approved the 2018 Employee Stock Purchase Plan (2018 ESPP).
- Auditor Ratification: Ernst & Young LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2018.
Voting Results and Shareholder Participation
As of the record date (May 25, 2018), there were 53,989,427 shares eligible to vote. A quorum of 42,374,525 shares (78.49%) was present.
| Matter | Votes For | Votes Against/Withheld | Abstentions | Broker Non-Votes |
|---|---|---|---|---|
| Election of Christopher Kiritsy | 22,289,290 | 5,458,537 (Withheld) | N/A | 14,626,698 |
| Election of Jean-Pierre Bizzari | 20,425,268 | 7,322,559 (Withheld) | N/A | 14,626,698 |
| 2018 EIP Approval | 26,267,510 | 1,461,082 | 19,235 | 14,626,698 |
| 2018 ESPP Approval | 27,405,863 | 327,319 | 14,645 | 14,626,698 |
| Auditor Ratification | 41,876,904 | 457,673 | 39,948 | 0 |
Guidance, Outlook, and Risks
This filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It strictly reports the results of the annual meeting and the adoption of equity plans.
Investor Verification Checklist
- Verify the specific terms of the 2018 EIP and 2018 ESPP by reviewing Exhibits 10.1 and 10.2 referenced in this filing.
- Confirm the total number of shares authorized for issuance under the new equity plans to assess potential dilution.
- Review the definitive Proxy Statement (Schedule 14A filed June 14, 2018) for detailed biographies of the newly elected directors and full plan descriptions.
- Note that the filing metadata in the request incorrectly identified the company as "Palvela Therapeutics, Inc."; the actual registrant is Pieris Pharmaceuticals, Inc.